For example, long-term anti-inflammatory therapy targeting IL1-β in patients with MI with a proinflammatory blood profile [Canakinumab Anti-Inflammatory Thrombosis Outcomes Study] reduces the risk of recurrent cardiovascular events.43 Here, IL1B is linked to myocardial infarction.